PHASE-II TRIAL OF TRIMELAMOL IN REFRACTORY OVARIAN-CANCER

被引：8
|
作者：
JUDSON, IR
CALVERT, AH
GORE, ME
BALMANNO, K
GUMBRELL, LA
PERREN, T
WILTSHAW, E
机构：
[1] INST CANC RES,MED SECT,SUTTON SM2 5PX,SURREY,ENGLAND
[2] ROYAL MARSDEN HOSP,LONDON,ENGLAND
来源：
BRITISH JOURNAL OF CANCER | 1991年 / 63卷 / 02期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1038/bjc.1991.72
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.
引用
收藏
页码：311 / 313
页数：3
相关论文
共 50 条
  • [31] PHASE-II TRIAL OF MITOMYCIN-C PLUS 5-FU IN THE TREATMENT OF DRUG-REFRACTORY OVARIAN-CANCER
    ALBERTS, DS
    GARCIAKENDALL, D
    SURWIT, EA
    SEMINARS IN ONCOLOGY, 1988, 15 (03) : 22 - 26
  • [32] A PHASE-II TRIAL OF ADJUVANT CISPLATIN AND DOXORUBICIN IN STAGE-I EPITHELIAL OVARIAN-CANCER
    DOTTINO, PR
    PLAXE, SC
    COHEN, CJ
    GYNECOLOGIC ONCOLOGY, 1991, 43 (03) : 203 - 205
  • [33] TENIPOSIDE (VM-26) IN PATIENTS WITH ADVANCED REFRACTORY OVARIAN-CANCER - A PHASE-II STUDY OF THE NETHERLANDS JOINT STUDY-GROUP FOR OVARIAN-CANCER
    VANDERBURG, MEL
    HUININK, WWT
    VRIESENDORP, R
    VANOOSTEROM, AT
    NEIJT, JP
    VERMORKEN, JB
    VANPUTTEN, WLJ
    KOOIMAN, A
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (07): : 997 - 998
  • [34] CARBOPLATIN AND IFOSFAMIDE IN OVARIAN-CANCER PHASE-II AND PHASE-III TRIALS
    WILTSHAW, E
    PERREN, TJ
    FRYATT, ID
    BLAKE, PR
    HARPER, P
    SLEVIN, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 : S48 - S50
  • [35] A PHASE-II NUDE-MOUSE MODEL FOR HUMAN OVARIAN-CANCER
    BOVEN, E
    SCHLUPER, H
    ERKELENS, C
    LUNING, M
    PINEDO, H
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 431 - 431
  • [36] A PHASE-II STUDY OF CYPROTERONE-ACETATE IN ADVANCED OVARIAN-CANCER
    THOMPSON, P
    OSBORNE, R
    SLEVIN, M
    WRIGLEY, P
    WILTSHIRE, E
    BLAKE, P
    HARPER, P
    COLEMAN, R
    MORRIS, D
    WILLIAMS, C
    SWEETENHAM, J
    YOUNG, A
    LEONARD, R
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 518 - 518
  • [37] PHASE-II AND PHARMACOKINETIC STUDY OF LOBAPLATIN IN PATIENTS WITH RELAPSED OVARIAN-CANCER
    GIETEMA, JA
    VELDHUIS, GJ
    GUCHELAAR, HJ
    WILLEMSE, PHB
    UGES, DRA
    CATS, A
    BOONSTRA, H
    VANDERGRAAF, WTA
    SLEIJFER, DT
    DEVRIES, EGE
    MULDER, NH
    BRITISH JOURNAL OF CANCER, 1995, 71 (06) : 1302 - 1307
  • [38] PHASE-II STUDY OF PIRARUBICIN COMBINED WITH CISPLATIN IN RECURRENT OVARIAN-CANCER
    DUBOIS, A
    MEERPOHL, HG
    MADJAR, H
    SPINNER, D
    DALL, P
    PFISTERER, J
    BAUKNECHT, T
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, 120 (03) : 173 - 178
  • [39] PHASE-II EVALUATION OF BLEOMYCIN IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER
    BLACKLEDGE, G
    LAWTON, F
    BUCKLEY, H
    CROWTHER, D
    CANCER TREATMENT REPORTS, 1984, 68 (03): : 549 - 550
  • [40] PHASE-II TRIAL OF FLUTAMIDE IN ADVANCED OVARIAN-CANCER - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY
    TUMOLO, S
    RAO, BR
    VANDERBURG, ME
    GUASTALLA, JP
    RENARD, J
    VERMORKEN, JB
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (07) : 911 - 914
12345